Continuous Glucose Monitoring as an alternative for Cystic Fibrosis Related diabetes screening and diagnosis
Authors' conclusion
In this exploratory study, glucodensities show better discriminatory capacity than HbA1c and CGM classic metrics in distinguishing early mild CFRD. This study supports the need for future larger prospective studies to define the most accepted screening method for CFRD, as well as the optimal cut-off point of CGM metrics and/or glucodensities for the diagnosis of CFRD.
Study context
- Population
- Patients with cystic fibrosis with an Oral Glucose Tolerance Test (OGTT) within the previous 6 months who accepted wearing a Continuous Glucose Monitoring (CGM) sensor for 14 days
- Participants
- 38 patients
- Comparison
- HbA1c, classical CGM metrics and glucodensities vs OGTT for Cystic Fibrosis Related Diabetes (CFRD) diagnosis
- Outcome
- Ability of HbA1c, classical CGM indexes and glucodensities to distinguish CFRD based on OGTT
Methodological detailsprospective, observational, exploratory
- Prospective
- Observational
- Exploratory
Performance
As reported in the abstract
Diagnostic accuracy for CFRD
| Test or model | Sensitivity | Sensitivity and specificity | Specificity |
|---|---|---|---|
| CGM TAR >180 mg/dL >6 % | 93 % (p = 0.042) | — not stated in the abstract | — not stated in the abstract |
| CGM TAR >140 mg/dL >20 % | — not stated in the abstract | — not stated in the abstract | 90 % (p = 0.032) |
| Glucodensities | — not stated in the abstract | over 85 % | — not stated in the abstract |
Sensitivity
CGM TAR >180 mg/dL >6 %93 % (p = 0.042)
CGM TAR >140 mg/dL >20 %— not stated in the abstract
Glucodensities— not stated in the abstract
Sensitivity and specificity
CGM TAR >180 mg/dL >6 %— not stated in the abstract
CGM TAR >140 mg/dL >20 %— not stated in the abstract
Glucodensitiesover 85 %
Specificity
CGM TAR >180 mg/dL >6 %— not stated in the abstract
CGM TAR >140 mg/dL >20 %90 % (p = 0.032)
Glucodensities— not stated in the abstract
— not stated in the abstract
Further findings
Patient preferences for CFRD screening
- Preference for a simpler method such as HbA1c; CGM better accepted than OGTT
Original publication
Continuous Glucose Monitoring as an alternative for Cystic Fibrosis Related diabetes screening and diagnosis. Diabetes Res Clin Pract. Published 19 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →